Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4.

H El-KhayatY FouadH I MohamedH El-AminEnas M KamalM MaherA Risk

Published in: Alimentary pharmacology & therapeutics (2018)

The SOF/DCV combination therapy has proven efficacy and safety in treating patients with hepatitis C-related liver cirrhosis genotype 4 in a large cohort of patients in the real world.

Keyphrases

combination therapy
hepatitis c virus
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
hepatitis c virus infection
patient reported outcomes